In the "Executive Decision" segment, Cramer sat down with Ron Squarer, CEO of Array BioPharma ( ARRY), another speculative biotech company fighting the war against cancer. Shares of Array are up 64% so far in 2013. Squarer said one of the big reasons for his company's success has been having great partners. He said Array has partnered with a number of big names in the industry and has learned a lot while helping to bring many new exciting treatments to fruition. That said, Squarer also said any biotech's success comes down to two things: good science and excellent decisions, both of which Array has been fortunate to have in recent years. Squarer highlighted a few projects, including a partnership with Onyx Pharmaceuticals ( ONXX) for a drug they call "520." He said there should be news out by the end of the year for this blood cancer treatment. Also on the horizon, 502, the company's asthma treatment, which is potentially the first major advance in 15 years in that area. Cramer said that like Pharmacyclics, Array is another great speculative way to play the many advances that are being made in the fight against cancer.
In his "Mad Tweets" segment, Cramer followed up on a few stocks that stumped him during earlier shows. He said Nektar Threrapeutics ( NKTR), which saw its shares plummet 24% today after one of its drugs failed to make the grade, should be held until the company's analyst day on Oct. 8. Cramer said that all the good news is already baked into the stock of GT Advanced Technologies ( GTAT), and he'd wait for a pullback before considering it. Turning to two IPOs from May, Cramer said Insys Therapeutics ( INSY) may have already risen 320% for the year but it remains reasonably valued. He was not impressed with Cyan ( CYNI), which missed its first quarter as a public company. When asked about International Paper ( IP), Cramer said a recent downgrade was wrong. He was less enthusiastic about Westport Innovations ( WPRT), saying that while he still likes the story, the company needs a lot more financing. Finally, Cramer said that he's still bullish on GameStop ( GME) ahead of the new game cycle and would buy shares on any weakness. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.-- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC